Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85
Benzinga Newsdesk 1 year ago
NewsPrice TargetSmall CapAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $60 to $85.
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $60 to $85.